Did Christopher Jacobs buy Reata Pharmaceuticals stock?

Common questions

Did Christopher Jacobs buy Reata Pharmaceuticals stock?

Yes. Christopher Jacobs disclosed 1 purchase and 1 sale of Reata Pharmaceuticals (RETA) stock between Dec 28, 2020 and Jan 4, 2021, in STOCK Act reports. Added together, the disclosed purchases come to $1K-$15K and the disclosed sales to $1K-$15K.

How big were Christopher Jacobs's Reata Pharmaceuticals trades?

STOCK Act reports give a range for each trade, such as $1K-$15K, never an exact amount. Added together, the disclosed purchases come to $1K-$15K and the disclosed sales to $1K-$15K.

Did Christopher Jacobs make these Reata Pharmaceuticals trades personally?

Not always. The STOCK Act requires members to report trades by themselves, a spouse and dependent children. The owner column of each linked filing says whose trade it was.

Does Christopher Jacobs still own Reata Pharmaceuticals stock?

This page lists reported trades, not holdings. A purchase can have been sold since, and the filings shown do not say what is held today.

When did Christopher Jacobs report these trades?

The latest filing is dated Feb 17, 2021. The STOCK Act gives members of Congress 45 days to report a trade, so a filing can trail the trade by weeks. Every row shows both dates.

Where does this data come from?

From periodic transaction reports filed under the STOCK Act with the Clerk of the House. Every trade links to the original filing.